Company awarded commercial Drug Establishment License (DEL) for Canada following successful inspection of C3i’s contract development and manufacturing organization (CDMO) facility.

C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.

The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL approval recognizes C3i as having industry-leading expertise, regulatory know-how, and strong quality standards.

“The C3i team worked hard to meet the requirements of a DEL and are proud that we received approval from Health Canada to commercially manufacture cell therapies.” – Louisa Petropoulos, CEO of C3i. “We are excited to be the first CDMO in Canada to reach this milestone, and there is more to come. Our goal is to manufacture cell and gene therapies for the global market. We expect to have the European Medicines Agency (EMA) conduct their inspection later this fall.”

C3i supports its clients in process development, scale-up and manufacturing for phase 1 to phase 3 clinical trials, as well as commercial cell and gene-modified cell therapies. C3i continues to expand its capabilities to include the production of viral vectors, exosomes, and other autologous and allogeneic cellular therapies.

About C3i Center Inc

C3i is a full-service, in-house CDMO with a vision to make life-saving cell and gene therapies available to everyone who needs them. C3i provides services to biotechnology companies, academic research groups, and pharmaceutical companies, supporting the advancement and commercialization of innovative technologies. C3i’s dedicated team is focused on providing clients with tailored services to meet their specific needs, expediting their innovative pipeline from development to commercial. C3i prides itself on delivering on-time, cost-efficient quality results. In-house services include phase-appropriate quality control testing, biomarker discovery, immune monitoring and diagnostic testing with College of American Pathologists (CAP)-accredited laboratories.

To learn more about who we are, visit www.c3icenter.com and for business inquiries, please contact our VP of Business Development, Sandra Donaldson, at sdonaldson@centrec3i.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620081082/en/

sdonaldson@centrec3i.com

Logo

Tags

More Like This

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

AGC Biologics Honored by Customers and Industry Leaders for Excellence in Contract Development and Manufacturing

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

Solvias Opens Center of Excellence for Biologics and Cell & Gene Therapy in Research Triangle Park

Curia Receives 2024 CDMO Leadership Award